Back to Journals » Neuropsychiatric Disease and Treatment » Volume 5

Effect of milnacipran on suicidality in patients with mild to moderate depressive disorder

Authors Avedisova, Borodin V, Zakharova K, Aldushin A

Published 31 July 2009 Volume 2009:5 Pages 415—420

DOI https://doi.org/10.2147/NDT.S5467

Review by Single-blind

Peer reviewer comments 3


Alla Avedisova, Vladimir Borodin, Ksenia Zakharova, Artem Aldushin

Department of Borderline Psychiatry, FGU State Scientific Research Center of Social and Forensic Psychiatry “V.P. Serbsky”, Moscow, Russia

Abstract: The presence of suicidal manifestations (thoughts and behavior) was studied in a cohort of 30 patients with mild to moderate depression during a 6-week treatment with the serotonin-norepinephrine reuptake inhibitor, milnacipran. At baseline mild suicidal thoughts were present in 46.7% of patients, the mean Hamilton Depression Rating Score (HDRS17) was 23.9 ± 1.8 and the mean suicidality score on the Beck Scale for Suicidal Ideation (BSS) was 4.9 ± 4.9. Suicidal thoughts decreased progressively throughout the study in parallel with other depressive symptoms. At no time during treatment was there any indication of an increased suicidal risk. Notably, the items retardation and psychic anxiety on the HDRS17 decreased in parallel. This may possibly explain the lack of any “activation syndrome”, which is occasionally observed at the early stages of therapy with some antidepressants and may be linked to a temporary increase in suicidal ideation. To our knowledge this is the first detailed report of suicidality during treatment with milnacipran.

Keywords: suicidality, milnacipran, depression

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]